GeneSystem Co Ltd
KOSDAQ:363250
GeneSystem Co Ltd
Research & Development
GeneSystem Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
GeneSystem Co Ltd
KOSDAQ:363250
|
Research & Development
-₩3.2B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩208B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-14%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Research & Development
-₩20.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
GeneSystem Co Ltd
Glance View
Genesystem Co., Ltd engages in providing PCR based molecular diagnostic products. The firm is engaged in the development, manufacture and sale of platform based on molecular diagnosis. The firm develops and manufactures products such as molecular diagnosis systems, biochips, test kits, and reaction reagents, among others. The firm develops in vitro diagnostic technology through immunodiagnosis technology and molecular diagnosis technology.
See Also
What is GeneSystem Co Ltd's Research & Development?
Research & Development
-3.2B
KRW
Based on the financial report for Dec 31, 2024, GeneSystem Co Ltd's Research & Development amounts to -3.2B KRW.
What is GeneSystem Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-22%
Over the last year, the Research & Development growth was 4%. The average annual Research & Development growth rates for GeneSystem Co Ltd have been -5% over the past three years , -22% over the past five years .
